tirzepatide osa fda approval Approves Zepbound for Obstructive Sleep Apnea with Obesity Tirzepatide for the Treatment of

In SELECT, a multicenter trial of patients with overweight or obesity and preexisting cardiovascular disease, semaglutide 2.4 mg reduced weight and the risk of major adverse cardiovascular events while also improving glycated hemoglobin (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride levels [16, 17]

Qsymia carries pregnancy risks (topiramate causes birth defects), a more complex side effect profile including cognitive effects from topiramate, and it requires participation in a REMS risk management program

They snack less

For women seeking a menopause-specific clinical pathway, structured programs are available that incorporate: Hormonal assessment, including systemic estradiol and progesterone evaluation when clinically appropriate Dose calibration based on metabolic markers Ongoing monitoring Structured lean mass preservation If you are exploring clinician-guided microdosing within a defined menopause framework, you can review available compounded GLP-1 calibration options below